Drug intelligence / Profile preview

orphenadrine + acetaminophen + caffeine + diclofenac sodium

Development stage
Preclinical
Lead developer
Ache Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

This is a fixed-dose combination drug containing orphenadrine, acetaminophen, caffeine, and diclofenac sodium. The formulation is designed to provide synergistic effects for the management of acute musculoskeletal pain and inflammation. - **Orphenadrine** is a centrally acting muscle relaxant with anticholinergic properties that helps relieve muscle spasm and associated pain. - **Acetaminophen** (paracetamol) acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. - **Caffeine** serves as a central nervous system stimulant and can enhance the analgesic effect of other components. - **Diclofenac sodium** is a nonsteroidal anti-inflammatory drug (NSAID) that provides anti-inflammatory, analgesic, and antipyretic effects primarily through inhibition of cyclooxygenase enzymes COX-1 and COX-2[5]. The primary indication for this combination is the treatment of acute painful musculoskeletal conditions such as postural low back pain[5]. The rationale behind combining these agents is to achieve comprehensive relief by targeting different mechanisms involved in pain perception, inflammation, and muscle spasm.

Brand names
Tandrilax
Other names
orphenadrine + acetaminophen + caffeine + diclofenac sodiumorphenadrine citrate + acetaminophen + caffeine + diclofenac sodium
02

Targets

ADOR (Adenosine receptors)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)NMDAR (Glutamate receptor ionotropic, NMDA)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on orphenadrine + acetaminophen + caffeine + diclofenac sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on orphenadrine + acetaminophen + caffeine + diclofenac sodium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call